For research use only. Not for therapeutic Use.
BTD is a selective transient receptor potential canonical 5 (TRPC5) activator. BTD can be used for the research of neurological disease[1].
BTD can activate TRPC5 with an EC50 values of 1.4 μM (fluorometric microwell Ca2+ influx analyses) and 1.3 μM (in whole cell patch clamp experiments), respectively[1].
BTD can activate TRPM8-expressing HEK293 cells with an EC50 values of 20.6 μM[1].
BTD can activate heteromeric channel complexes consisting of TRPC5 and its closest relatives TRPC1 or TRPC4[1]
| Catalog Number | I023764 |
| CAS Number | 896684-04-1 |
| Synonyms | N-[3-(1-adamantyloxy)propyl]-3-(6-methyl-1,1-dioxo-4H-1λ6,2,4-benzothiadiazin-3-yl)propanamide |
| Molecular Formula | C24H33N3O4S |
| Purity | ≥95% |
| InChI | InChI=1S/C24H33N3O4S/c1-16-3-4-21-20(9-16)26-22(27-32(21,29)30)5-6-23(28)25-7-2-8-31-24-13-17-10-18(14-24)12-19(11-17)15-24/h3-4,9,17-19H,2,5-8,10-15H2,1H3,(H,25,28)(H,26,27) |
| InChIKey | YXADKMPRWFBOHW-UHFFFAOYSA-N |
| SMILES | CC1=CC2=C(C=C1)S(=O)(=O)N=C(N2)CCC(=O)NCCCOC34CC5CC(C3)CC(C5)C4 |
| Reference | [1]. Beckmann H,et al. A benzothiadiazine derivative and methylprednisolone are novel and selective activators of transient receptor potential canonical 5 (TRPC5) channels. Cell Calcium. 2017;66:10-18. |
